South San Francisco, CA, United States

KaloBios Pharmaceuticals

www.kalobios.com
South San Francisco, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
KaloBios Pharmaceuticals, Monash University and Ludwig Institute for Cancer Research | Date: 2017-08-02

The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of solid tumors.


The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.


Patent
KaloBios Pharmaceuticals | Date: 2015-04-02

The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.


Patent
KaloBios Pharmaceuticals | Date: 2015-05-14

The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists.


Patent
KaloBios Pharmaceuticals | Date: 2016-03-02

The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.


Patent
KaloBios Pharmaceuticals | Date: 2014-10-08

The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.


Patent
KaloBios Pharmaceuticals | Date: 2015-12-14

The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the V_(H )and V_(L )sequences of the reference antibody with sequences from human antibody repertoires. The invention also provides novel compositions comprising hybrid immunoglobulin variable domains containing a combination of frameworks (FRs) and CDRs from different antibody clones.


The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.


Patent
KaloBios Pharmaceuticals | Date: 2013-12-30

The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.


The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.

Loading KaloBios Pharmaceuticals collaborators
Loading KaloBios Pharmaceuticals collaborators